Texas researchers found that neutrophils, a type of immune cell, release oxidized mitochondrial DNA, triggering immune reactions in systemic lupus erythematosus (SLE). The findings provide insights into key disease mechanisms, which might be employed in the development of new therapies for this complex and devastating disease. The research team at…
A research team from the University of California, Los Angeles, has shown that certain types of gut bacteria might be crucial in reducing both cancer and inflammation, a finding with long-reaching implications for diseases with an inflammatory component, such as lupus. Intestinal bacterial flora holds both beneficial species and those with…
French company NEOVACS announced that its Investigational New Drug (IND) application for IFNα Kinoid in lupus, now in Phase 2b development, was approved by the South Korean Health Authority. NEOVACS was established in 1993. Today, the biotech is a leader in active immunotherapy technology platforms (Kinoids) for autoimmune and/or inflammatory diseases. NEOVACS…
Patients with systemic lupus erythematosus (SLE) showed significant improvements and decreased disease severity when treated with a combined therapy of belimumab and standard of care measures for up to 24 months, according to results of a two-year study. The study, “Response to belimumab among patients with systemic…
A new edition of “The Autoimmune Connection: Essential Information for Women on Diagnosis, Treatment and Getting on with Your Life” received praise from the American Autoimmune Related Diseases Association (AARDA), which called the book “the ultimate resource for women with autoimmune diseases.” Written by the award-winning journalist Rita Baron-Faust and lupus…
A study published in the Journal of Experimental Medicine demonstrates that a particular cell-signalling protein is crucial for the formation of autoreactive B-cells in systemic lupus erythematosus (SLE), but not for the formation of B-cells fighting infections. The finding of this autoimmune mechanism opens up the possibility for the development…
QuesGen Systems, a provider of research services to organizations and scientists working on brain health and treatments for traumatic brain injury (TBI), is expanding its business and has announced the establishment of a new business relationship with ImmunArray, a private diagnostics company with headquarters in Rehovot, Israel, and…
The bone disorder known as idiopathic osteonecrosis of the femoral head (ONFH) might be caused by high-dose steroid therapy — a common treatment for systemic lupus erythematosus (SLE). A research team at Kyoto University Hospital, Japan, has developed a minimally invasive method to save the thighbone from breaking down,…
In systemic lupus erythematosus (SLE) patients, intestinal dysbiosis is associated with activation of pro-inflammatory cells. As such, rescuing gut microbiota with beneficial bacteria strains improves patients’ inflammatory profile, according to a study entitled “Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients”…
Corbus Pharmaceuticals announced the addition of a protocol amendment to one of the company’s existing Investigational New Drug (IND) Applications with the FDA for a Phase 2 clinical trial of Resunab for the treatment of systemic lupus erythematosus (SLE), an important step to initiate a multicenter placebo-controlled SLE trial. The clinical study,…